Amylyx Pharmaceuticals' (AMLX) 'Buy' Rating Reiterated at HC Wainwright

Analysts maintain positive outlook on biotech firm's lead drug candidate

Mar. 28, 2026 at 6:48am

Got story updates? Submit your updates here. ›

HC Wainwright, a prominent investment bank, has reiterated its 'buy' rating on shares of Amylyx Pharmaceuticals (NASDAQ:AMLX), a biopharmaceutical company focused on developing treatments for rare neurological diseases. The analysts have also maintained their $34 price target on the stock, indicating potential upside from the company's current trading levels.

Why it matters

Amylyx's lead product, AMX0035, was recently approved by the FDA for the treatment of amyotrophic lateral sclerosis (ALS), a rare and debilitating neurological condition. The reiteration of the 'buy' rating and price target by HC Wainwright suggests that the analysts remain confident in the company's ability to successfully commercialize AMX0035 and potentially expand its pipeline of treatments for other neurological diseases.

The details

In their report, the HC Wainwright analysts cited Amylyx's strong clinical data, experienced management team, and potential for future pipeline expansion as key factors supporting their positive outlook on the stock. The analysts also noted that Amylyx has secured partnerships and funding to support the launch and ongoing development of AMX0035.

  • Amylyx Pharmaceuticals reported its latest quarterly earnings on March 3, 2026.
  • HC Wainwright issued its reiteration of the 'buy' rating and $34 price target on March 28, 2026.

The players

Amylyx Pharmaceuticals

A biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases, with a focus on leveraging novel approaches to target cellular pathways implicated in neurodegeneration.

HC Wainwright

A prominent investment bank that has reiterated its 'buy' rating and $34 price target on Amylyx Pharmaceuticals' stock.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Amylyx's progress in commercializing AMX0035 and any updates on the company's pipeline of potential new treatments for neurological diseases.

The takeaway

Amylyx Pharmaceuticals' lead drug candidate, AMX0035, has received a positive endorsement from HC Wainwright, a respected investment bank, as the company looks to capitalize on the recent FDA approval and expand its portfolio of treatments for rare neurological conditions.